Scopia Capital Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Scopia Capital Management’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-5,703,587	Closed	-$16.9M	–	50
2016 Q3	$16.9M	Hold	5,703,587	–	–	0.3%	32
2016 Q2	$8.5M	Hold	5,703,587	–	–	0.18%	39
2016 Q1	$21.1M	Hold	5,703,587	–	–	0.39%	31
2015 Q4	$57.6M	Hold	5,703,587	–	–	1.14%	24
2015 Q3	$77.6M	Buy	5,703,587 +275,001	+5%	+$4.9M	1.66%	19
2015 Q2	$103M	Buy	5,428,586 +78,746	+1%	+$1.7M	2%	15
2015 Q1	$140M	Hold	5,349,840	–	–	3.03%	12
2014 Q4	$112M	Buy	5,349,840 +326,060	+6%	+$8.22M	2.09%	15
2014 Q3	$168M	Buy	5,023,780 +2,124,195	+73%	+$65.9M	3.42%	9
2014 Q2	$93M	Buy	+2,899,585	New	+$108M	2.4%	15

Scopia Capital Management's AEGR Position: Q4 2016 in Review

Scopia Capital Management sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 5,703,587 shares — an estimated $16.9M sold.

Scopia Capital Management first reported a position in AEGR in Q2 2014 and held it in 10 quarters. The position peaked at $168M in Q3 2014. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

Scopia Capital Management reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Scopia Capital Management sold 5,703,587 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $16.9M.
Scopia Capital Management first reported a position in Aegerion Pharmaceuticals in Q2 2014 and held it in 10 quarters.
Scopia Capital Management's Aegerion Pharmaceuticals position peaked at $168M in Q3 2014.
0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Scopia Capital Management's 13F filing for Q4 2016, filed 15 Feb 2017.